Aminopeptidase N (rat)
Aminopeptidase N (rat) (APN/CD13) is a Zn2+-dependent membrane-bound exopeptidase that preferentially degrades proteins and peptides with N-terminal neutral amino acids. Aminopeptidase N (rat) is inhibited by angiotensin IV and participates in the regulation of angiotensin IV half-life in the rat striatum.
For research use only. We do not sell to patients.
- CAS No.: 9054-63-1
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Aminopeptidase N (rat) accounted for 60 % of the total aminopeptidase activity in rat striatal cell membranes[1].
Aminopeptidase N (rat)'s over-expression reduces basolateral Na+/K+ ATPase activity and abundance in LLCPK-1 proximal tubule cells, with this effect dependent on signaling via the AT4 receptor[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Aminopeptidase N (rat) (intracerebroventricular infusion; microinfusion into paraventricular nucleus of the hypothalamus) reduces arterial blood pressure in both spontaneously hypertensive and normotensive rats, with a more pronounced effect in spontaneously hypertensive rats, via an angiotensin type 1 receptor-dependent mechanism[2].
Aminopeptidase N (rat) has increased renal abundance and activity in salt-resistant rat strains fed a high-salt diet, supporting a role in renal salt adaptation and blood pressure regulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 250-300 g)[1]
-
Dosage:10 nM, 100 nM, 500 nM
-
Administration:local perfusion via microdialysis probe; 60 min
-
Result:Caused no significant change in extracellular dopamine concentrations in the rat striatum, with levels remaining near baseline (100%) throughout and after perfusion (10 nM, 100 nM, 500 nM inhibitor 7B alone).
Potentiated the angiotensin IV-induced increase in striatal dopamine levels, resulting in a maximal increase of approximately 350% of baseline at 60 min of co-perfusion.
Completely abolished the angiotensin IV-induced dopamine increase, with dopamine levels remaining at baseline (500 nM inhibitor 7B + 10 µM angiotensin IV, combined APN and IRAP inhibition).
Chemical Information
-
CAS No. 9054-63-1
-
SMILES
[Aminopeptidase N (rat)]
-
Synonyms
APN/CD13
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
[1]. Stragier B, et al. Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res. 2007;1131(1):97-105. [Content Brief]
[2]. Danziger RS, et al. Aminopeptidase N in arterial hypertension. Heart Fail Rev. 2008;13(3):293-298. [Content Brief]
[3]. Sjöström H, et al. Structure and function of aminopeptidase N. Adv Exp Med Biol. 2000;477:25-34. [Content Brief]
[4]. Wickström M, et al. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102(3):501-508. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)